Bifurcation Stenting: IVUS and OCT Information

Similar documents
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD

Non-LM bifurcation studies of importance in 2011

Lessons for technique and stent choice

FFR-guided Jailed Side Branch Intervention

New Generation Drug- Eluting Stent in Korea

Nobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy

EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Bifurcation stenting with BVS

LCX. President / Director of Cardiology / New Tokyo Hospital

LM stenting - Cypher

PCI for In-Stent Restenosis. CardioVascular Research Foundation

PROMUS Element Experience In AMC

Why I try to avoid side branch dilatation

Bench test : Is it still useful? Do we need standardization?

Potential Benefit of Final Kissing Balloon Inflation After Single Stenting for the Treatment of Bifurcation Lesions

Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank

Update from the Tryton IDE study

Clinical Application of OCT in Stent Evaluation

OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT

6 th European Bifurcation Club October BUDAPEST. Kissing in simple strategy? Why and how I kiss. Y. Louvard, ICPS, Massy France

Plaque Shift vs. Carina Shift Prevalence and Implication

Inspiron Stent. Clinical Research Program. Pedro A. Lemos MD PhD. Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?

Drug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester

PCI for Long Coronary Lesion

IN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

DESolve NX Trial Clinical and Imaging Results

Drug Eluting Stents: Bifurcation and Left Main Approach

Insight from the CACTUS trial Coronary Bifurcation Application of the Crush

Unprotected LM intervention

Bifurcation Stenting. European Bifurcation Club update. Ioannis Iakovou, MD Onassis Cardiac Surgery Center Athens, Greece

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April Session: Left mains & bifurcation intervention

BIOFREEDOM: Polymer free Biolimus A9 eluting

Medtronic Symposium The Complex Bifurcation Patient: new insights into stent selection

eluting Stents The SPIRIT Trials

Clinical Value of OCT. Guidance for Coronary Stenting. Giulio Guagliumi, MD

Evaluation COMBO s Healing Profile The EGO-COMBO Serial OCT Study

DISCOVER Ultimaster with Optical Frequency Domain Imaging

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?

Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent. Masahiko Ochiai MD, FACC, FESC, FSCAI

Side Branch Occlusion

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

The Spectrum of Dedicated Stents for Bifurcation Lesions: Current Status and Future Projections. Martin B. Leon, MD

The BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino

ΣΥΜΠΛΟΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΔΙΧΑΣΜΩΝ

IVUS-Guided d Provisional i Stenting: Plaque or Carina Shift. Soo-Jin Kang, MD., PhD.

Welcome to the 8 th European Bifurcation Club October Barcelona

Drug eluting balloons in CAD

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI

Protection of side branch is essential in treating bifurcation lesions: overview

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

Left main coronary artery (LMCA): The proximal segment

Stent Thrombosis in Bifurcation Stenting

Very late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography

Side branch occlusion in 500 ABSORB BVS

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

Biodegradable Stents An update and work-in

Strategies for PCI of SVG

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)

Run-Lin Gao, MD, FACC. On Behalf of I-LOVE-IT Trial Investigators

Drug eluting stents (DES) have decreased

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience

Usefulness of OCT during coronary intervention

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

Bifurcations Bad Krozingen I

Taking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe

What Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas

What Stent to Use? JASVINDAR SINGH MD, FACC

A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations

COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands

Contemporary therapy of bifurcation lesions

Insights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up

Bioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals

Integrated Use of IVUS and FFR for LM Stenting

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France

Final Kissing Ballooning Returns? The analysis of COBIS II registry

Post PCI functional testing and imaging: case based lessons from FFR React

PCI for Bifurcation Coronary Lesion

Stents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved.

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators

CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer

Insight from Nordic III

TNT Session. The latest clinical evidence in diabetics for the Amphilimus TM eluting polymer-free DES. Rafael Romaguera, MD

Element Clinical Program Perseus Late Breaking News and the Platinum Study Design

INTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY. SeQuent Please NEO CLINICAL EVIDENCE AND COST / BENEFIT EFFECTIVENESS

Vascular Responses in Patients With and Without Diabetes Mellitus After Everolimus-Eluting Stent Implantation

In-Stent Restenosis. Can we kill it?

Acta Cardiol Sin 2018;34: doi: /ACS _34(2) A

PCI for Left Anterior Descending Artery Ostial Stenosis

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.

Current DES designs and expansion capacity testing

Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo

OCT guidance for distal LM lesions

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

Transcription:

Bifurcation Stenting: IVUS and OCT Information Yoshinobu Murasato MD, PhD (New Yukuhashi Hospital) On behalf of J-REVERSE investigators October 14-15, 2011, Lisbon

Proximal stent deformation induced by KB inflation a a b b c d d c KB inflation caused oval-shape dilation with the eccentricity value of 0.75 and 30% enlargement e was obtained compared to distal site. Guérin P. Circ Cardiovasc Interv, 2010, 3, 120 Murasato Y, EBC 2010 e

Intimal growth Symmetrical vs. Asymmetrical expansion Symmetrical Homogenous intimal growth Asymmetrical Uneven intimal growth Frequent uncovered struts thrombus Otake H, JACC Intrv, 2009, 2,459

Impact of symmetricity KBT SEI: stent eccentricity index NUS: neointima unevenness score Otake H, JACC Intrv, 2009, 2,459

Japanese Registry Study in Comparison between Everolimus-eluting Stent and Sirolimus-eluting Stent for the Bifurcation Lesion Principal Investigators Yoshinobu Murasato (New Yukuhashi Hospital) Yoshihisa Kinoshita (Toyohashi Heart Center) Core laboratory QCA, QCU: Cardiovascular Imaging Center (Toyohashi) OCT: Kobe University (J REVERSE)

Purpose of the study Study-1 To compare the long-term outcome of provisional stenting between EES and SES deployment. Study-2 To prove the following hypothesis Asymmetrical expansion in the bifurcation lesion leads to frequent inhomogeneous intimal growth on the strut and thrombus attachment.

Study design 300pts Bifurcation lesion Provisional stenting 75% stenosis in MV with /wo SB stenosis ( 75% ) Size: MV 2.5mm SB 2mm Lesion length < 46mm EES (Xience V / Promus) SES (Cypher select plus) KBT (+) KBT (-) KBT (+) KBT (-)

Study protocol Before PCI Post PCI Mo Mo Y EES SES CAG + + + + IVUS + + OCT + (n=100) ECG, blood sample Clinical event + + + + + + + + + +

Endpoint Study-1 1. Major adverse cardiac event (MACE) at 3Y Death Myocardial infarction Target lesion revascularization (TLR) Target vessel revascularization (TVR) Stent thrombosis Study-2 1. The following OCT findings Unevenness of intimal growth Number of uncovered struts Frequency of thrombus attachment Relation between stent eccentricity index in IVUS 2. Relation between the above factors and MACE at 3Y

Study enrollment From July 2010 till Sept, 2011 2010 2011 Group Patient No. EES KBT+ EES KBT- SES KBT+ SES KBT- 74 58 34 23 Total 189

Patient background 189 patients Age 67.4 +/- 9.2 y.o. Male 78.3% HT 74.1% Dyslipidemia 68.8% DM 40.7% Insulin 6.3% Smoking history 58.7% Previous MI 15.3% Previous PCI 30.7% Access Radial 74.6% Femoral 25.4% Guiding catheter 6Fr 75.7% 7Fr 19.6% 8Fr 3.7%

IVUS: Stent Eccentricity Index in the MV 0.95 0.9 0.85 0.8 0.75 : p<0.05 vs. KBT- : p<0.1 vs. KBT- SES KBT+ EES KBT+ SES KBT- EES KBT- (n = 8) (n = 8) (n = 8) (n = 8) 0.7 P6 P5 P4 P3 P2 P1 P0 D0 D1 D2 D3 D4 D5 D6

400 350 300 IVUS volumetric analysis Percent change in the MV after PCI 450 140 140 (%) (%) (%) * Lumen * 120 Vessel 120 Plaque prox MV dist MV KBT+ * P<0.05 vs. KBTprox vs. dist P<0.05 250 200 100 100 150 100 EES KBT+ EES KBT- SES KBT+ SES KBT- 80 EES KBT+ EES KBT- SES KBT+ SES KBT- 80 EES KBT+ EES KBT- SES KBT+ SES KBT-

(%) 140 IVUS volumetric analysis Percent change in the SB after PCI 120 100 80 60 EES KBT+ SES KBT+ 40 20 0 Lumen Vessel Plaque

Experience in Kobe University* *OCT core laboratory of J-REVERSE De Novo Native Coronary Artery Lesions at True Bifurcation Treated with DES N=76 Non-FKI N=43 FKI N=33 Cypher N=27 Taxus Liberte N=16 Cypher N=22 Taxus Liberte N=11 Hariki H, Shinke T, Otake H, Shite J et al. ACC2011

Distal segment 5 mm Segment location Hariki H, Shinke T, Otake H, Shite J et al. ACC2011 Bifurcation segment Proximal segment 5 mm Distal segment (Analized every 1mm) Bifurcation segment (Analized every cross section) Proximal segment (Analized every 1mm)

Neointimal thickness (µm) OCT analysis Hariki H, Shinke T, Otake H, Shite J et al. ACC2011 SO Bifurcation AO %Uncoverd strut = Number of uncovered struts / total struts AO OO %Malapposed strut = Number of malapposed struts / total struts AO : Adjacent to the orifice SO : Side branch orifice Jailed strut OO :Opposite to the orifice

Thrombus attachment (1) P=0.046 50 40 30 20 10 46.5 24.2 0 Non-FKI FKI Hariki H, Shinke T, Otake H, Shite J et al. ACC2011

Thrombus attachment (2) Non - FKI FKI Proximal AO * Bifurcation Distal OO SO # Prox Bifurc Dist * p=0.02, # P<0.1 Prox Dist Bifurc Hariki H, Shinke T, Otake H, Shite J et al. ACC2011

%Uncovered strut in bifurcation segment Non-FKI(n=43) FKI(n=33) P Over all 12.2±10.3% 5.0±5.8% P=0.0006 AO 10.8±16.6% 4.5±6.4% P=0.0424 SO 20.1±30.3% 18.7±32.5% P=0.8694 OO 11.6±14.5% 5.0±8.6% P=0.0217 AO : Adjacent to the orifice SO : Side branch orifice OO : Opposite to the orifice Hariki H, Shinke T, Otake H, Shite J et al. ACC2011

%Malapposed strut in each segment Non-FKI (n=43) FKI(n=33) P Distal segment Bifurcation segment (at AO,OO) Proximal segment 2.26±5.93% 0.38±1.04% P=0.0754 1.70±5.50% 0.39±1.00% P=0.1828 4.19±9.28% 1.37±5.79% P=0.1311 Hariki H, Shinke T, Otake H, Shite J et al. ACC2011

mm 0.15 0.1 0.05 0 The increase of NIT and JSCT from 6M F/U to 12M F/U Non - jailed strut NIT P=0.02 mm Jailed strut NIT 0.2 P=0.006 0.1 0.118±0.087 vs 0.140±0.088 0 0.070±0.053 vs 0.105±0.059 JSCT NIT Neointimal thickness mm Jailed strut complex thickness 0.6 P 0.001 0.4 0.2 0 0.286±0.157 vs 0.406±0.162 Hariki H, Shinke T, Otake H, Shite J et al. ACC2011

The increase of NIT and JSCT from 6M F/U to 12M F/U mm Growth of JSCT: 0.12mm P 0.001 / 6M 0.16 More growth in the future? Thrombogenic? 0.12 P=0.126 0.12 0.08 0.04 0.02 0.04 0 Non jailed Strut- NIT Jailed strut-nit JSCT Hariki H, Shinke T, Otake H, Shite J et al. ACC2011

Conclusion KB inflation brings asymmetrical expansion which may lead to a risk of disturbance of endthelialization and the J-REVERSE has approached this issue. There is no significant difference between SES and EES in the stent deformation induced by KB inflation in the preliminary data. KB inflation induces more expansion of the lumen volume in the distal MV and reduces uncovered struts and thrombus attachment around the bifurcation compared to the treatment without it. The jailed strut complex increases its thickness more than the neointimal growth in any other site, which may evoke a concern on the thrombosis on the jailed strut.